Skip to main content
. 2023 May 15:1–20. Online ahead of print. doi: 10.1038/s41577-023-00877-7

Fig. 2. Timeline of approval of key protein kinase inhibitor drugs for cancer and immune-mediated disease.

Fig. 2

The timeline lists the year of approval and indication, starting with the approval of cyclosporine for allograft transplantation (in 1989) to the approvals of JAK inhibitors (JAKinibs) for immune-mediated diseases to date. AA, alopecia areata; AD, atopic dermatitis; BCR, B cell receptor; BTK, Bruton’s tyrosine kinase; CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; EGFR, epidermal growth factor receptor; GVHD, graft versus host disease; ITP, immune thrombocytopenia; JAK, Janus kinase; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; ROCK; RHO-associated kinase; SYK, spleen tyrosine kinase; TGFβ, transforming growth factor-β; VEGFR, vascular endothelial growth factor receptor.